MONTE ROSA THERAPEUTICS, INC.

Analyst Reco. Monte Rosa Therapeutics, Inc.

Equities

GLUE

US61225M1027

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
5.54 ^USD	+0.73%		-8.58%	-1.95%

Mar. 14	Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline	MT
Mar. 14	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Starts Monte Rosa Therapeutics With Outperform Rating, $11 Price Target	Feb. 15	MT
Credit Suisse Trims Monte Rosa Therapeutics' Price Target to $11 From $12, Keeps Neutral Rating	23-03-17	MT
Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Price Target at $18	23-01-03	MT
UBS Initiates Coverage on Monte Rosa Therapeutics With Buy Rating, $22 Price Target	22-10-13	MT
Jefferies Starts Monte Rosa Therapeutics at Buy With $20 Price Target	22-08-15	MT
Piper Sandler Adjusts Price Target on Monte Rosa Therapeutics to $21 From $40, Reiterates Overweight Rating	22-05-12	MT
Credit Suisse Initiates Monte Rosa Therapeutics at Neutral, $19 Price Target	22-04-28	MT
Berenberg Bank Adjusts Monte Rosa Therapeutics' Price Target to $28 From $32, Maintains Buy Rating	22-03-30	MT
Wells Fargo Starts Monte Rosa Therapeutics at Equalweight With $19 Price Target	22-02-09	MT
Guggenheim Adjusts Price Target for Monte Rosa Therapeutics to $35 From $40, Maintains Buy Rating	22-01-03	MT
Berenberg Bank Initiates Coverage on Monte Rosa Therapeutics With Buy Rating, $32 Price Target	21-11-17	MT
MONTE ROSA THERAPEUTICS : SVB Leerink Starts Monte Rosa Therapeutics at Market Perform with $20 Price Target	21-10-14	MT
MONTE ROSA THERAPEUTICS : JPMorgan Initiates Monte Rosa Therapeutics at Overweight Rating With $38 Price Target	21-07-19	MT
MONTE ROSA THERAPEUTICS : Cowen Initiates Coverage on Monte Rosa Therapeutics With Outperform Rating	21-07-19	MT
MONTE ROSA THERAPEUTICS : Piper Sandler Starts Monte Rosa Therapeutics at Overweight With $40 Price Target	21-07-19	MT
MONTE ROSA THERAPEUTICS : Guggenheim Starts Monte Rosa Therapeutics at Buy With $30 Price Target	21-07-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer